CASI CASI Pharmaceuticals Inc

Price (delayed)

$1.24

Market cap

$173.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$115.01M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
CASI's revenue has soared by 115% YoY and by 26% QoQ
CASI's gross profit is up by 46% QoQ
The equity has increased by 50% year-on-year but it has declined by 5% since the previous quarter
CASI Pharmaceuticals's net income has decreased by 32% YoY but it has increased by 3.3% from the previous quarter
CASI Pharmaceuticals's quick ratio has decreased by 38% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
139.8M
Market cap
$173.35M
Enterprise value
$115.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.83
Price to sales (P/S)
7.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.24
Earnings
Revenue
$21.96M
EBIT
-$51.98M
EBITDA
-$48.75M
Free cash flow
-$30.56M
Per share
EPS
-$0.42
Free cash flow per share
-$0.22
Book value per share
$0.68
Revenue per share
$0.16
TBVPS
$0.94
Balance sheet
Total assets
$144.53M
Total liabilities
$27.03M
Debt
$2.01M
Equity
$94.8M
Working capital
$73.48M
Liquidity
Debt to equity
0.02
Current ratio
8.33
Quick ratio
7.85
Net debt/EBITDA
1.2
Margins
EBITDA margin
-222%
Gross margin
58.5%
Net margin
-236.7%
Operating margin
-261.6%
Efficiency
Return on assets
-37.5%
Return on equity
-56.5%
Return on invested capital
-96.9%
Return on capital employed
-38.6%
Return on sales
-236.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
-0.8%
1 week
-8.15%
1 month
-19.48%
1 year
-18.42%
YTD
-57.97%
QTD
-20%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$21.96M
Gross profit
$12.84M
Operating income
-$57.44M
Net income
-$51.98M
Gross margin
58.5%
Net margin
-236.7%
CASI's revenue has soared by 115% YoY and by 26% QoQ
CASI's gross profit is up by 46% QoQ
The operating income has contracted by 42% YoY
The net margin has increased by 39% year-on-year and by 23% since the previous quarter

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.83
P/S
7.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.24
CASI's EPS is up by 9% since the previous quarter but it is down by 2.4% year-on-year
The stock's P/B is 54% below its 5-year quarterly average of 4.0 and 39% below its last 4 quarters average of 3.0
The equity has increased by 50% year-on-year but it has declined by 5% since the previous quarter
CASI's revenue has soared by 115% YoY and by 26% QoQ
CASI's P/S is 51% below its last 4 quarters average of 16.0

Efficiency

How efficient is CASI Pharmaceuticals business performance
CASI's return on sales is up by 39% year-on-year and by 23% since the previous quarter
CASI's ROIC is up by 39% YoY and by 19% from the previous quarter
The ROA has grown by 12% from the previous quarter and by 4.3% YoY
The return on equity is up by 12% since the previous quarter but it has declined by 2.5% year-on-year

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
The total assets has soared by 58% year-on-year but it has declined by 2.4% since the previous quarter
CASI Pharmaceuticals's quick ratio has decreased by 38% YoY and by 8% from the previous quarter
The debt is 98% smaller than the equity
The equity has increased by 50% year-on-year but it has declined by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.